DNA interaction of selected tetrahydropyrimidine and its effects against CCl4‐induced hepatotoxicity in vivo: Part II

Abstract

AbstractTetrahydropyrimidine (compound A = methyl 4‐[4′‐(heptyloxy)‐3′‐methoxyphenyl]‐1,6‐dimethyl‐2‐thioxo‐1,2,3,4‐tetrahydropyrimidine‐5‐carboxylate) was chosen for in vivo studies after exhibiting noteworthy in vitro activity against the K562 and MDA‐MB‐231 cell lines, with IC50 values of 9.20 ± 0.14 µM and 12.76 ± 1.93 µM, respectively. According to experimental (fluorescence titration, viscosity, and differential scanning calorimetry) results, A interacts with DNA via the minor groove. In vivo, acute oral toxicity studies in Wistar albino rats proved no noticeable symptoms of either toxicity or death during the follow‐up period. Genotoxic and antigenotoxic studies at three different concentrations of A (5, 10, and 20 mg/kg of body weight) in Wistar albino rats showed that the dose of 5 mg/kg body weight did not cause DNA damage and had a remarkable DNA protective activity against CCl4‐induced DNA damage, with a percentage reduction of 78.7%. It is also important to note that, under the investigated concentrations of A, liver damage is not observed. Considering all experimental outcomes realized under various in vivo investigations (acute oral toxicity, genotoxicity, antigenotoxicity, and biochemical tests), compound A could be a promising candidate for further clinical testing.